Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Bertaglia, Valentina, Parati, Maria Chiara, Borgonovo, Karen, De Silva, Pushpamali, Luciani, Andrea, Novello, Silvia, Scartozzi, Mario, Emens, Leisha A., Solinas, Cinzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792383/
https://www.ncbi.nlm.nih.gov/pubmed/36549170
http://dx.doi.org/10.1016/j.breast.2022.12.004
Descripción
Sumario:The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients. This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone.

Ejemplares similares